Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

3.0%

2 terminated/withdrawn out of 66 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

24%

16 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

13 recruiting

Enrollment Performance

Analytics

Phase 2
22(34.9%)
Phase 1
17(27.0%)
Phase 3
12(19.0%)
N/A
8(12.7%)
Phase 4
4(6.3%)
63Total
Phase 2(22)
Phase 1(17)
Phase 3(12)
N/A(8)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (66)

Showing 20 of 66 trials
NCT07519109Phase 1Not Yet Recruiting

Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery.

Role: lead

NCT07288814Phase 1Not Yet Recruiting

Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

Role: collaborator

NCT07239765Phase 3Completed

A Study to Evaluate the Safety, Efficacy, and PPK of ABCD in Patients With IMD

Role: lead

NCT07026968Phase 3Enrolling By Invitation

A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

Role: lead

NCT04138719Phase 2Recruiting

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Role: collaborator

NCT04159142Phase 2Recruiting

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Role: collaborator

NCT05173246Phase 2Recruiting

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Role: collaborator

NCT07014540Phase 4Not Yet Recruiting

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

Role: collaborator

NCT06562894Phase 2Not Yet Recruiting

Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients

Role: lead

NCT05299164Phase 1Active Not Recruiting

GVM±R in Patients With Relapsed or Refractory Aggressive NHL

Role: collaborator

NCT06958692Phase 3Recruiting

A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder

Role: lead

NCT06943950Phase 3Not Yet Recruiting

A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis

Role: lead

NCT05457829Phase 2Recruiting

Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study

Role: collaborator

NCT06921044Phase 2Not Yet Recruiting

A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL

Role: collaborator

NCT05707832Phase 3Completed

A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus

Role: lead

NCT06894797Not ApplicableRecruiting

Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.

Role: collaborator

NCT06571461Phase 3Not Yet Recruiting

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

Role: lead

NCT04728035Phase 1Completed

Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance

Role: lead

NCT06511739Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

Role: lead

NCT05009953Phase 2Terminated

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

Role: lead